Major Melbourne study a world-first for AMD

An Australian-led study has received $5 million to undertake the world’s most intensive investigation into why a particular group of age-related macular degeneration (AMD) patients are at greater risk of vision loss. Read more

Traces of anti-VEGF drugs found in breast milk

Anti-vascular endothelial growth factor (anti-VEGF) drugs have been identified in breast milk, prompting warnings from the researchers that the use of these medications during breastfeeding could affect developing infants. Read more

FDA clears Novartis’ new treatment for nAMD

Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea. Read more